Those waiting for Hikma and Vectura’s copy of GlaxoSmithKline blockbuster Advair may be waiting awhile.

Merck's antiviral business suffered some serious blows this year, but it now boasts a new product: Prevymis, a CMV fighter approved by the FDA on Thursday.

Five more lawmakers are piling on Allergan for the company's controversial tribal licensing deal.

Score a win for pharma in the state-by-state war over drug costs: Ohioans have refused a measure that would have set pricing limits.

Novartis is blazing ahead with its bid to take its CAR-T therapy Kymriah into new realms with a double-pronged application in Europe.

Valeant has overcome manufacturing problems at a Bausch & Lomb plant to win approval of its long-delayed eye drug.

Congress hasn't made progress on pricing reform, but a group of lawmakers are pushing to reduce waste in pharmaceuticals.

AbbVie and J&J got a scare this Halloween when the FDA approved AstraZeneca’s Imbruvica rival Calquence.